{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-058306","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.848010+00:00","generated_at":"2026-05-24T11:03:32.784599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sionna Therapeutics FY2024 net loss $61.7M; cash $168M plus $199.6M IPO net proceeds extend runway into 2028","bullets":["Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.","Cash, equivalents and marketable securities $168.0M as of Dec 2024; excluding $199.6M net IPO proceeds from February 2025.","Upsized IPO raised $219M gross ($199.6M net) in Feb 2025; shares trading on Nasdaq under SION.","Phase 1 MAD dosing completed for SION-451; final MAD cohort for SION-719 planned; topline data expected H1 2025.","Plan to initiate Phase 2a POC trial in CF patients H2 2025 with topline data mid-2026; combination MAD trials also planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-058306","json":"https://secwatch.observer/filing/0001193125-25-058306.json","markdown":"https://secwatch.observer/filing/0001193125-25-058306.md","text":"https://secwatch.observer/filing/0001193125-25-058306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000119312525058306/0001193125-25-058306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000119312525058306/d679677d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:03:32.784599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}